Your session is about to expire
← Back to Search
Other
Cooling Helmets for Concussion (ColdCon Trial)
N/A
Recruiting
Research Sponsored by Spectrum Health - Lakeland
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 72 hours
Awards & highlights
No Placebo-Only Group
Summary
This trial tests if a cooling helmet can help adults with mild traumatic brain injuries recover faster. The helmet cools the head and neck to lower brain temperature, potentially reducing symptoms. Patients will be monitored for symptom severity and side effects over a few days. Cooling has been studied as a method to reduce symptoms and pathological changes after concussive injuries.
Who is the study for?
This trial is for individuals aged 19-65 who've had a mild traumatic brain injury with symptoms like headaches within the first day of injury. They must have a Glasgow Coma Scale score over 13 and be able to consent. It's not for pregnant women, those with certain medical conditions, or severe migraines.
What is being tested?
The study tests if cooling helmets (Catalyst Cryohelmet) can help reduce concussion symptoms after a head injury. Participants will use the helmet and their symptoms will be tracked using interviews over three days to see if there's improvement.
What are the potential side effects?
Potential side effects may include discomfort from cold temperatures, skin irritation where the helmet contacts the head, and possible worsening of pre-existing conditions sensitive to cold exposure.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 72 hours
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~72 hours
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Post-Concussion Symptom Severity Score Index case report form
Secondary study objectives
Pharmaceutical Preparations
Pharmaceutical Preparations
Patient Returns to Baseline Function of 0 by 1 hour survey
+2 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Catalyst Cryohelmet intervention with symptomatic careExperimental Treatment1 Intervention
The treatment arm will receive symptomatic care (acetaminophen 1000mg and ondansetron 4mg) along with 30 minutes of head-neck cooling in the emergency department while being monitored for side effects.
Group II: Control: symptomatic care armActive Control1 Intervention
The control arm will receive symptomatic care (acetaminophen 1000mg and ondansetron 4mg). They will not wear any helmets.
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Traumatic Brain Injury (TBI) include symptomatic care, rest, and gradual return to activity. Head and neck cooling, a treatment being studied, aims to reduce brain temperature, which can help mitigate secondary injury processes such as inflammation and metabolic dysfunction.
This cooling effect can decrease the intensity and duration of symptoms, prevent further injury, and promote recovery. Other standard interventions focus on maintaining adequate cerebral perfusion and oxygenation, controlling intracranial pressure, and preventing complications like seizures.
These treatments are crucial for improving neurological outcomes and enhancing the overall recovery process for TBI patients.
The evidence for hypothermia as a neuroprotectant in traumatic brain injury.
The evidence for hypothermia as a neuroprotectant in traumatic brain injury.
Find a Location
Who is running the clinical trial?
Spectrum Health - LakelandLead Sponsor
13 Previous Clinical Trials
1,309 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have vomited more than twice after an injury.I am younger than 19 or older than 65.I do not need immediate life-saving medical help.I do not have a disability that prevents me from reporting my symptoms accurately.I have a blood cancer such as leukemia, lymphoma, or multiple myeloma.I have a history of liver issues or conditions related to cold sensitivity.I have a known brain mass, intracranial hemorrhage, or skull fracture.I have no cuts or bleeding on my scalp.I have had a headache or head injury in the last 24 hours.
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Research Study Groups:
This trial has the following groups:- Group 1: Control: symptomatic care arm
- Group 2: Catalyst Cryohelmet intervention with symptomatic care
Share this study with friends
Copy Link
Messenger